To The Moon

Chinese company is selling 100 million shares in listing Li Auto follows rival XPeng in selling shar

June 17 - Conviction in the strength of the economic recovery pushed investors into U.S. technology stocks on Thursday, driving the Nasdaq higher, although a post-Fed hangover left a subdued S&P nursing a very minor loss.The marginal decline was the S&P's third negative finish in a row, while the Dow - with a more pronounced drop - posted its fourth straight lower close.Many investors were still processing the Federal Reserve's unexpectedly hawkish message on monetary policy from the previous d

It’s another quiet week on the earnings front. Oracle on Tuesday, Lennar on Wednesday, and Adobe and

NEW YORK, June 11 - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected.Economically sensitive smallcaps and transports notched solid gains, outperforming the broader market.For the week, the S&P and the Nasdaq advanced from last Friday's close, while the Dow posted a weekly loss.But th

KEY POINTS CNBC’s Jim Cramer said not to underestimate the small gains stocks have put up in recent

Besides being targeted by above-average short interest, these companies are actually growing.

Firms are “flush with cash” and spending is at its highest in history, according to investment firmJefferies, which recommended dozens of U.S. and global stocks to play the trend.Jefferies’ capital expenditure — or capex — indicator is “going ballistic,” the bank said in a research note Monday, and there has been a surge in corporate spending on big-ticket goods such as ships, as well as on smaller items like plant equipment.Investment bankJPMorganalso picked stocks set to get a boost from the c

NEW YORK (Reuters) - Wall Street stocks struggled to eke out closing gains on Tuesday as a lack of c

(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer